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ABSTRACT 
 
Background. Besides neuron-specific factors, vascular alterations are involved in the 
pathogenesis of several age-dependent central nervous system (CNS) diseases. For example, the 
majority of cardiovascular risk factors are present in patients with Alzheimer’s disease (AD). 
Moreover, the levels of circulating bone marrow-derived progenitor cells increase in blood with 
the severity of AD, suggesting an active vascular damage and repair. Using co-expression 
analysis of peripheral blood mononuclear cells (PBMCs), we have previously identified a gene 
module centered on OLR1 (coding for LOX-1, the endothelial-specific receptor for oxidized 
LDL), that correlates with vascular function in normal individuals.  
Objective. The goal of the current study was to verify the hypothesis that this module is 
also altered in blood of patients with cardiovascular and neurodegenerative diseases.  
Methods. To this end, we downloaded from public databases and normalized Affymetrix 
GeneChips data of adult human PBMCs of patients and corresponding healthy controls. Then, 
we compared the expression levels of the members of a previously validated co-expression 
OLR1-centered module (OLRM). 
Results. The collective expression of OLRM members was significantly increased 
compared to controls in PBMCs from healthy pregnant women and in juvenile and adult patients 
with diabetes, in adult subjects with hyperlipidemia, and in seniors with AD, and was 
significantly decreased in women with multiple sclerosis. At the same time, changes in another 
gene module, centered on NOTCH4, were insignificant, confirming the specificity of the 
observed effects. The expression levels of OLRM members were collectively increased by statin 
treatment and by dietary omega-3 fatty acids containing lipids.  
  Conclusion. We expanded the biological validation of a peripheral blood transcriptional 
module that is increased in several conditions known to lead to or to derive from vascular 
dysfunction, including AD and MS, and to be sensitive to pharmacological (statins) and lifestyle 
(dietary) interventions. This suggests that OLRM qualifies as a new collective transcriptional 
biomarker for detection and monitoring of disease, including disorders of the CNS.  
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BACKGROUND AND RATIONALE 
 
1. Neurodegenerative diseases have an essential vascular component. Neurons are 
extremely specialized cells, with unique energetic needs (for oxygen, glucose, etc.). Moreover, 
their assembling in complex multicellular structures creates additional difficulties for metabolite 
diffusion to and from them. For this reason, the blood vessels are intimately integrated with the 
neurons or neuronal bundles that are anatomically organized as ‘neuro-vascular units’1. On the 
other hand, the structure and function of blood vessels, namely the vascular cells reactivity and 
subsequent vascular and microvascular perfusion, also essentially depend on their innervation1. 
Thus, it naturally follows that dysfunctions in one compartment translates in the malfunction of 
the other. 
A case in point is Alzheimer’s disease (AD), largely considered to be triggered by 
neuron-specific molecular defects, at least in the familial forms of the disease, but increasingly 
recognized to be triggered by neuro-inflammation2, and/or by a concurrent vascular pathology. In 
fact, some investigators are convinced that AD (at least in its late-onset forms), as well as other 
dementias, are mainly a consequence of cerebral hypoperfusion3 (Diagram 1).  
 
  
 
Here we summarize  the many apparent flaws of the ‘amyloid hypothesis’ of AD 
(following Jack C. de la Torre4): amyloid deposition has not yet been found to be neurotoxic in 
vivo; senile plaques are the products of sick neurons, thus they cannot also be the cause of their 
sickness, because a product is the result and not the cause of some activity; amyloid deposition in 
the brain does not relate with dementia severity; many patients without dementia have the same 
density of senile plaques as the patients with AD; amyloid deposition is not the earliest 
neuropathological event observed in those afflicted with the disease; alternatively, many 
Diagram 1. Presumed pathological pathways leading to the development of AD according to the 
amyloid or vascular hypotheses, and associated risk factors. In fact, these pathways may overlap 
and/or cross-talk to each other, as suggested by the arrows (modified after JC de la Torre, ref.4).  
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cognitively healthy elderly people have abundant senile plaques in the brain without signs of 
AD; amyloid deposition in the brain does not correlate to neuronal, metabolic, or synaptic loss; 
amyloid plaques can be found in other dementias, including vascular dementia. Also, in the pre-
clinical research realm, experiments with transgenic mice that produce amyloid beta deposits in 
the brain show, as in humans, no relation between such deposits and neuronal, metabolic, or 
synaptic loss; the same transgenic mice also show cognitive loss before amyloid is deposited in 
the brain; memory loss is independent of amyloid beta overexpression in transgenic mice; 
transgenic mice overexpressing an isoform of human amyloid peptide show low glucose 
metabolism and loss of glia in the absence of amyloid deposits, which suggests a neuronal-
energy deficit precedes amyloid deposition; in these mice with memory-impairment, 
vaccinations against amyloid over 8 weeks did not improve cognition. 
 
2. OLR1 is a genetic risk factor for AD. An abundance of genetic, epidemiological, 
comorbidity, neuroimaging, and risk 
factors overlap (summarized in 
Diagram 1, left side) and concur to 
suggest that the primary insult in AD 
(in the late-onset forms at least) might 
be targeting the brain 
(micro)vasculature4. Among those 
arguments is the fact that two major 
genetic polymorphisms associated with 
the emergence of this disease are 
related to lipoproteins in the 
circulation. One is the variant 4 of 
ApoE, which is a lipoprotein particle-
associated protein that interacts with 
low-density lipoprotein (LDL) 
receptors on cellular surfaces, although 
its function is considered to be mainly 
related to neuro-inflammation5. Another gene polymorphism, and possibly related to the first6, is 
one for OLR1, coding for the lectin-like oxidized low density lipoprotein receptor (LOX-1), the 
proposed endothelial ‘scavenger receptor’7.  
 
3. Role of OLR1/LOX-1 in endothelial and stem cells biology. This receptor  binds 
many other cell-damaging ligands8, such as glycosylated LDL, as well as other advanced 
glycosylation end-products (AGEs) occurring in diabetes. It is stimulated by angiotensin II9 that 
is excessively produced during hypertension. LOX1 mediates, via reactive oxygen species 
(ROS)10, both cellular damage (at high oxLDL concentrations) and tissue repair, mainly by 
stimulating neovascularization (when oxLDL is in lower amounts)11. LOXIN is a ‘splice variant’ 
Diagram 2. Putative role of OLR1/LOX-1 in bone marrow 
derived stem/progenitor cells (BMSC), as mediators of 
damage-repair coupling in blood-perfused organs. Note that 
mobilization of BMSC changes the pattern of gene expression 
in circulating peripheral blood mononuclear cells. 
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of OLR1-derived mRNA, coding for an isoform which can heterodimerized with LOX1 to block 
its deleterious effects at higher oxLDL concentrations12. However, the actual mechanism through 
which LOX-1 or LOXIN influences the course of AD remains to be determined.  
LOX-1 is also expressed in bone marrow-derived progenitor cells, being involved in 
these cells’ proliferation13 and in their recruitment to sites of injury14. Alternatively, LOX-1 is 
responsive to plasma lipid peroxidation status in a concentration-dependent manner, being 
detrimental for endothelial progenitor cells at higher oxLDL concentrations15.  
 
4. Blood contains cells with primitive characters which provide vascular protection 
and tissue repair. In the last decade it became clear that beside its traditional functions (e.g. 
carrying of nutrients and metabolic waste, protection against infections and blood loss, 
maintenance of its own fluidity in an optimal range, etc.), the blood has one more essential 
function: to contribute stem/progenitor cells from bone marrow-located reservoirs that help 
replace those cells lost due to wear-and-tear or to aging in various organs, including the brain 
(Diagram 2). This tissue-maintenance function could be acutely amplified in response to injury 
by the release of even more cells 
with a tissue-reparative function 
in the circulation after different 
forms of damage. However, due 
to their rarity, primitivity (i.e. 
un-differentiated state), and 
phenotypic plasticity, the 
characterization of these cells 
proved to be very difficult16.  
To address this 
limitation, the Moldovan lab is 
developing a new approach to 
detect and study the presence of 
these cells with a tissue-
reparative function in peripheral 
blood in both humans and mice, 
without the need to physically 
isolate them, or even to know a-
priori their characteristics. The 
method is based on the detection 
of their transcriptional signature 
in whole peripheral blood 
mononuclear cell (PBMC) 
preparations17. This approach is 
Figure 1.  A module of PBMCs transcriptional network with 
cardiovascular function defined by co-variation analysis. A. Panel 
of primitive (left column) and differentiation (right column) tested 
genes. B. Example of co-variation of primitive and cardiovascular 
genes in PBMCs from healthy human subjects (n=27). C. Co-
variation expression network of genes in PBMCs from normal 
subjects. A module composed of 15 genes (encircled) were inversely 
related to blood donor’s age, vascular stiffness and central blood 
pressure, suggesting a vascular protective role. D-F. Expansion of 
this network with the ‘neighborhoods’ of several ‘seed genes’ 
detected by genechips in PBMC from normal blood: (D) children, (E) 
healthy adults, and (F) burn victims (A-C from ref. 10; D-E were 
obtained with the contribution of T. Kantor, ASC Honors Thesis 
2014).  
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particularly well suited for the stem/progenitor cells system, because their state of preparedness 
for future differentiation is more inscribed in their mRNA, rather than in their proteins repertoire. 
So far, our group has found a cluster of genes which in the normal human population 
decreases with the age of blood donors, and is inversely related to their blood pressure and 
vascular stiffness (indicative of a vascular-protective function), while being directly proportional 
to body mass index (BMI)17.  
Of note, in a retrospective cohort study relating BMI to risk of dementia in two million 
people from UK, it was recently found that compared with people of a healthy weight, 
underweight people had a 34% higher risk of dementia. Furthermore, the incidence of dementia 
continued to fall for every increasing BMI category, with very obese people having a 29% lower 
dementia risk than people of a healthy weight. These patterns persisted throughout two decades 
of follow-up, after adjustment for potential confounders and allowance for the J-shape 
association of BMI with mortality18. These findings are in line with other observations leading to 
the so-called ‘obesity paradox’, indicating a rather protective effect of the adipose tissue in a 
variety of pathologies. One explanation could be that its presence mobilizes increased levels of 
circulating stem/progenitor cells with reparative function, from which the organism may 
indirectly benefit in conditions of tissue injury.  
This cluster of expressed genes (or ‘metagene’19), is organized as a module of the 
PBMCs transcriptional network. In other words, among the members of the module there is a 
special relationship making them somehow ‘equivalent’ to each other. One of the most 
parsimonious explanations, also known as the ‘principle of guilt-by-association’, is that these 
genes contribute to a common function20. If so, finding new members of a given module is a way 
to learn more about the collective roles those genes have in the organism, or even to assign new 
functions to genes with known or unknown roles.  
 
5. Expansion of the OLR1-containg gene cluster on microarrays. For this reason, our 
lab is performing a set of analyses aiming to detect new members of the gene module with 
cardiovascular function, using published studies performed on PBMC samples from normal 
subjects, and from patients with various cardiovascular and neurodegenerative diseases. All these 
studies whose rough data was uploaded in the GEO (Gene Expression Omnibus) database were 
performed on Affymetrix gene chips, rather than by Polymerase Chain Reaction (PCR), as in our 
original study17. The main difference is that, although more comprehensive, and thus more 
objective, in covering the human transcriptome, these gene ‘chips’ are far less sensitive than 
PCR at detecting low abundance RNA transcripts, as expected from those derived from rare 
stem/progenitor cells in the circulation. In fact, from the 15 members of our cardiovascular 
module, only two (OLR1 and Notch4) are detectable in PBMC from adult blood, and only four 
in children’s blood.  
Taking these genes as ‘seeds’ and constructing their associated co-variation networks, our 
group has found that while Notch4’s neighborhood varies according to the source of the blood, 
the network of OLR1 is similar in these conditions: in normal blood from children and normal 
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adults, in that of patients with severe burn injury, where it is markedly increased21, and in women 
with preeclampsia (a condition characterized by hypertension, vascular stiffness, increased 
lipoprotein oxidation and reduced placental angiogenesis)22, where this module represent the 
most down-regulated genes. These last two situations can be considered as a biological 
‘validation’ of an extended OLR1 module (OLRM), which we further used in the current study. 
Altogether, we formulated a gene expression co-variation module containing 29 members (Table 
1), which show a relatively homogenous connectivity (Fig. 1F).
 
Table 1. Genes composing the OLR1/LOX-1 module in PBMCs. 
 
6. Goal of current study. In line with the previous effort to expand the PCR-based 
cardiovascular module, the goal of this project was to further validate the OLRM against other 
cardiovascular conditions, and to assess its involvement in neuro-degenerative diseases.  
 
 
METHODS 
Studies Used: From the National Center for Biotechnology Information’s Gene 
Expression Omnibus (GEO) public database, we assembled a collection of Affymetrix 
GeneChip® Human Genome U133 Plus 2.0 arrays (platform GPL570). The following studies 
were used: GSE17449, GSE9006, GSE15932, GSE55100, GSE11393, GSE29680, GSE22255, 
GSE48060, GSE27034, GSE66134, and GSE18309. Information regarding these studies can be 
found in Table 2 on the next page. 
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Figure # Title GSE # Link
2 OLRM in pregnant women and impact of multiple sclerosis (MS).   17449 http://www.ncbi.nlm.nih.gov/pubmed/20126412
3a Amplification of OLRM expression in children with TIID 9006 http://www.ncbi.nlm.nih.gov/pubmed/17595242
3b Less coordinated increase in the expression OLR cluster members in adults with TIIB.  15932 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15932
4a Amplified OLRM expression in adult Type I diabetic patients. 55100 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55100
4b Minimal changes in the expression levels of genes of a NOTCH4-centered transcriptional cluster in Type I diabetes 55100 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55100
5a OLRM expression in human subjects with hyperlipidemia 11393 http://www.ncbi.nlm.nih.gov/pubmed/18681780
5b OLRM expression in human subjects with Alzheimers receiving omega-3 treatment 29680 http://www.ncbi.nlm.nih.gov/pubmed/22545106
6a Reflection of ischemic stroke on OLRM expression levels in PBMCs 22255 http://www.ncbi.nlm.nih.gov/pubmed/22453632
6b Reflection of acute myocardial infarction on OLRM expression levels in PBMCs 48060 http://www.ncbi.nlm.nih.gov/pubmed/24801707
6c Reflection of peripheral artery disease on OLRM expression levels in PBMCs 27034 http://www.ncbi.nlm.nih.gov/pubmed/22409835
7 Expression of OLRM genes in age-dependent cognitive disorders 66134 http://www.ncbi.nlm.nih.gov/pubmed/17215369
8 Whole Blood controls for the OLRM modifications in AD 18309 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18309
 
Table 2. Database sources used for preparation of the figures. 
 
Presence Score Detection: In order to determine presence scores (detection levels), 
Affymetrix Expression Console was used to perform MAS5 normalization. Certain genes were 
represented by more than one probe set, in which case the probe set with the highest presence 
score and signal (expression value) was used, while the rest were discarded. ‘Presence Score’ 
was calculated by percentage of all arrays in a study. If scores were ‘Marginal’, they were 
considered ‘Absent’ and discarded. 
 
SCAN Normalization: The Single-Channel-Array-Normalization (SCAN) method was 
used to normalize microarrays. This eliminated batch effects. Instead of the group of chips being 
analyzed, this method normalizes each chip to itself. This enabled the addition of microarrays to 
any individual study without affecting the normalization procedure. This method produced 
intensity values which were then used for co-variation analysis. 
Matrix and Network Construction: Partek Discovery Suite was used to perform 
Pearson correlation and Matrix analysis. Matlab Software and Ohio Supercomputer Services 
(OSC) were used to perform Clique Mining analysis. In order to find patterns in the gene co-
expression matrix data we generated, we utilized the network mining and merging workflow 
described by Xiang et al.23 We created an unweighted graph from a gene co-expression data set 
by generating an edge between any two genes with an absolute correlation value greater than 0.6. 
We then applied the Bron-Kerbosh algorithm24  to generate all maximal cliques. The network 
merge approach23 was applied to these cliques, using various density thresholds depending on the 
study. This guaranteed each resulting sub-network induced a sub-matrix with an average 
correlation value greater than the threshold used on the original gene co-expression matrix. 
Gephi was finally used to visualize the discovered networks. 
Data Analysis: T-tests, linear regressions, and standard deviations were calculated using 
Microsoft Excel 2010. p < 0.05 was considered significant in all of the statistical analyses.  
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 RESULTS 
1. OLRM in development-related pathology. 
1.a Pregnancy and multiple sclerosis (MS). 
Pregnancy is associated with higher circulating levels 
of progenitor cells, deemed to be mostly of fetal –rather 
than maternal– origin25. These circulating progenitors 
seem to play a protective/reparative role for the 
mother’s tissues, such as the heart26 and brain27. 
Moreover, pregnancy was shown to ease the course of 
some severe diseases, such as multiple sclerosis (MS)28. 
This makes it likely that the same progenitor cell pool 
in the mother’s blood could help repair the damage of 
an ongoing pathological condition. However, these 
circulating fetal cells alone expectedly might not 
eliminate a maternal disease, particularly if it is related 
to the pregnancy itself, but still ease its course.  
Recent studies suggest that the placenta of 
pregnant women with PE express high levels of lectin-
like oxidized LDL receptor-1 (LOX-1), which induces 
endothelial dysfunction by increasing reactive oxygen 
species (ROS) and decreasing intracellular NO29.  
The observation that the OLRM is decreased in 
preeclampsia30, prompted us to verify whether the 
amplitude of this gene cluster is increased in women 
with normal pregnancy in the first place.  We found this 
to indeed be the case, as shown in Fig. 2A, which 
illustrates the dramatic increase of the module in the 
PBMCs from pregnant women, as compared with an 
age-matched control group. The very good linearity 
(regression R2=0.98, not shown) indicates that all genes coincidently are (and thus non-
randomly) modified and proportionally changed in the same direction, as expected from a tightly 
coupled transcriptional module. 
Next, we compared the OLRM in women with normal pregnancies and those pregnant 
women suffering from MS. This time, all members of the OLRM presented smaller relative 
levels of expression, but again with a very good proportionality in the changes (Fig. 2B), 
indicative of depletion in the peripheral blood of these women of the OLRM-generating cells, or 
altering of their function and/or transcriptional profile. However, when we compared pregnant 
women with MS with non-pregnant MS patients (Fig. 2C), those bearing a child presented much 
higher (and again proportionally-changed) values of the OLRM expression. This is in agreement 
Figure 2. OLRM in pregnant women and 
impact of multiple sclerosis (MS). A. 
Pregnancy dramatically increases the 
expression of all OLRM members. B. 
Mothers with MS present a decrease in 
OLRM expression as compared to normal 
pregnancy. C. However, pregnant MS 
women have substantially higher 
expression in OLRM as compared to non-
pregnant MS female patients. 
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with a model in which the pregnancy itself provides protection 
and/or repairing activity in women with MS, presumably 
helping with the easing of their symptoms. 
 
1.b. OLRM in children’s blood. Previously we found that, 
although quite insensitive to detecting the expression of low 
abundance transcripts, the microarrays showed more members 
of the cardiovascular module to be present in children’s blood 
than in adults (Fig 1D). This is consistent with the idea that, 
corresponding to this developmental stage, juvenile blood 
contains more primitive and/or less differentiated cells.  
Next, we analyzed the OLRM membership in blood of 
children with acquired (Type II) diabetes. This condition is 
known to lead to a decrease in circulating progenitor cells31, 
however when considering more subtle diabetes-related side 
effects, such as diabetic retinopathy, these cells were often found to 
be increased32-34. In our study, all members of the OLRM were 
larger in diabetic children (Fig. 3A), although the amplitude of this 
effect might have been modified (or, likely reduced) by the 
administered insulin and/or by other anti-diabetic medication. 
 
 
 
2. OLRM in adult vascular heath and disease. 
 
2.a. Diabetes.  As a major risk factor for cardiovascular 
diseases, diabetes’ impact on the circulating cell system with 
vascular-protective role, and its associated transcriptional profile, 
deserves a special consideration. For this reason, we downloaded 
more databases from studies comparing the effect of both types of 
diabetes on gene expression in PBMCs. The changes in the OLRM 
observed in Type II diabetic children were clearly present in adults 
as well (Fig. 3B). However, the proportionality among individual 
genes was less pronounced than in the previous studies, possibly 
due to either the result of medication or of the concurrent 
pathologies these adult patients might have. 
 When we compared the impact of Type I diabetes on the 
expression of the OLRM metagene in adult human patients, the 
results were even more impressive, both in amplitude (Fig. 4A) and 
in linearity of co-variation (not shown). To verify the specificity of 
Figure 3. Effect of diabetes on OLRM. A. 
Amplification of OLRM expression in 
children with TIID. B. Less coordinated 
increase in the expression OLR cluster 
members in adults with TIIB.   
Figure 4. Specificity of OLRM 
modifications in diabetes. A. 
Amplified OLRM expression in adult 
Type I diabetic patients. B. Minimal 
changes in the expression levels of 
genes of a NOTCH4-centered 
transcriptional cluster in blood 
samples from the same patient 
population.  
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this effect, we performed exactly the same analysis on the genes that belong to the Notch4 
module (Fig.1E), and we found that the modifications in this gene cluster in adults with Type I 
diabetes were minimal (Fig. 4B).   
 
2.b. Hyperlipidemia. The other major co-morbidity in the development of 
cardiovascular diseases is 
hyperlipidemia, either with increased 
low-density lipoprotein (LDL) 
cholesterol levels, or with increased 
triglycerides (associated with the very 
large low density lipoproteins, or 
VLDL). Assessing the influence of 
lipid disturbances on the OLRM 
structure has twofold value. First, it 
goes in line with the previous 
thinking, namely that these metabolic 
anomalies that alter the frequency in 
the peripheral blood35 and/or 
functions36 of the circulating 
progenitor cells system should be 
reflected in the express genes. Second, 
we may learn more about the very 
reason of co-variation in the expression of different genes with OLR1, the gene coding for the 
oxidized LDL. However, the latter assumption depends on whether increased LDL particles in 
plasma also mean an augmentation of their lipid peroxidation, which might or might not be the 
case, given the involvement of endogenous and exogenous (e.g. dietary) antioxidants.  
 We analyzed the OLRM in a population with familial hypercholesterolemia, before and 
after institution of an efficient treatment with atorvastatin, one of the most frequently prescribed 
statins.  Compared with age-matched controls, the hyperlipidemics had slightly but uniformly 
decreased values of OLRM members (Fig. 5A). After treatment, these values increased to levels 
making the differences completely disappear (Fig. 5A), as an indication of both specificity and 
sensitivity of the effect.  
Here should be underlined the power of our covariation analysis, as compared to single-
molecular markers: while the absolute changes of gene members of OLRM could be indeed low 
and/or individually non-significant, they have a strong statistical significance as a group (not 
shown).  
 
Figure 5. OLRM expression in human subjects with 
hyperlipidemia, and effect of statin treatment. OLRM 
expression before and after statin treatment in a 
human population with familial hypercholesterolemia, 
as compared with normo-lipidemic controls. 
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2.c. OLRM in cerebro- and cardio-vascular 
pathology. Next, we asked the question as to whether the 
systemic changes in proportions of cells with primitive 
characters (interpreted as mobilization of bone marrow 
derived progenitor cells) occurring in peripheral blood after 
major acute vascular events such as stroke37  or myocardial 
infarction38 are reflected in corresponding modifications in 
the OLRM. 
To this end, we compared OLRM-related gene 
expression profiling in patients with acute ischemic stroke 
(Fig. 6A), PBMCs samples from one-time and recurrent 
myocardial infarction patients, and from peripheral arterial 
disease patients with the corresponding matched controls. 
Overall, the differences were smaller and less coordinated 
than in some of the previous comparisons, but still 
statistically significant (better seen in stroke and one-time 
infarction) when compared as 
groups, rather than individually. 
Of note, all these blood samples 
were collected from patients 
pharmacologically treated for 
their condition (often with either 
disease specific treatment such 
as insulin for diabetes39 or with poly-medication), interventions which are known to affect the 
circulating progenitor cells, thus possibly explaining the small amplitude of the observed effects. 
In acute myocardial infarction (AMI), the 
changes in the OLRM were more notable in those 
patients with the first attack, rather those with recurrent 
presentations (Fig. 6B).  Also, given the known 
increase in soluble LOX-1 (sLOX-1) in peripheral 
artery disease associated with diabetes 40, we sought to 
determine the changes, if any, in OLRM expression in 
PBMCs. The results show that a change does happen, 
Figure 6. Reflection of large-vessel cardiovascular pathology 
on OLRM expression levels in PBMCs.  A. Comparison of OLRM 
in patients with and without ischemic stroke. B. Changes of 
OLRM with AMI (one-time or recurrent). C. Expression of OLRM 
module members in patients with peripheral artery disease as 
compared with a normal control population.  
 
Figure 7. Expression of OLRM genes in age-dependent 
cognitive disorders. A. Comparison of OLRM changes in PBMCs 
with mild cognitive impairment (MCI) of blood donors, and with 
Alzheimer's Disease (AD). This graded modification indicates 
that OLRM reflects a disease stage-dependent process. B. 
Comparison for the Notch4 cluster members in the same 
patient population. C. Beneficial effect of an omega-3 enriched 
diet on OLRM in PBMCs of AD patients. 
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although at a very small level (Fig. 6C). Supposedly, the observed association with sLOX-1 
might derive from the impact of diabetes itself, rather than the vascular dysfunction. 
 
 
3. OLRM in age- and vascular-dependent neuro-degenerative diseases.  
 
3.a. Alzheimer’s disease (AD). As detailed in the background, the pathogenesis of AD has a 
substantial cerebrovascular component. If a vascular damage/repair cycle is ongoing, this could 
be translated into a modified profile of relevant genes in the blood cells. To test this hypothesis, 
we analyzed gene expression data from patients with mild cognitive impairment (MCI), AD and 
Parkinson’s disease (PD). Fig. 7A shows a progressive, severity dependent increase in overall 
expression of OLRM genes (although MCI did not reach the statistical significance). 
Remarkably, this change was specific for OLRM, because the Notch4 module again did not 
show comparable changes in these patient 
populations (Fig. 7B). Interestingly, a diet rich in 
omega-3 poly-unsaturated fat tended to further 
increase OLRM as compared to untreated subjects. 
When detection of the same genes was 
attempted in whole blood, rather than in PBMCs, 
the differences between AD and controls became 
minimal (Fig. 8A), arguing for a ‘dilution’ of the 
target translated genes in the abundant erythrocyte 
and neutrophil-derived mRNAs.  
Finally, much less substantial –if any–
differences were found between OLRM genes in 
PBMCs from PD and normal age-matched controls 
(Fig. 8B), in support for the specificity of this 
metagene for a vascular, rather neuronal, pathology.  
 
 
 
 
 
DISCUSSION 
 
In this section we’ll comment on the main results of the study, and on their relevance for the 
field. First, we found that the OLRM indeed behaves collectively, as expected from a tightly-
coupled ‘metagene’, displaying strong covariation in comparisons leading to either very large 
(e.g. pregnancy, diabetes, AD), or small changes (acute vascular events, hyperlipidemia, dietary 
interventions). 
Figure 8. Further controls for the OLRM 
modifications in AD. A. No changes were 
seen when whole blood from AD patients 
was compared with normal controls, 
suggesting an mRNA dilution effect. B. 
Minimal increase in OLRM in PBMCs from 
Parkinson’s disease patients.  
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These changes were meaningfully 
associated with cardiovascular pathology 
as expected. Pregnancy in itself seems to 
be the strongest amplifier of the OLRM in 
peripheral blood, in accord with a 
mobilization of cells of fetal origin. 
Encouragingly for a vascular 
determination of several 
neurodegenerative diseases, two 
conditions (MS and AD) also presented 
strong changes in the OLRM levels. MS 
presented a decrease in expression of the 
OLRM members, while AD presented an 
increase in expression of the OLRM 
members, corresponding to the known 
behavior of circulating progenitor cells in 
these pathologies. 
Our findings warrant opening a line of 
experiments to directly confirm the origin 
of the OLRM in a given primitive cell 
class, and their functional relevance (as 
summarized in Diagram 3). If confirmed, 
these findings could establish a new 
collective biomarker for 
neurodegenerative conditions of vascular origin. Moreover, it is expected that targeting any of 
the OLRM members might modify coordinately all other members; this expands the power of 
drug searching significantly  
As with other discoveries, the identification of OLRM raises as many new questions as 
problems it may solve. Among the most pressing are: a. Cellular origin of the detected genes; in 
fact, it is likely to be not a specific cell class, but the collective contributions of all PBMCs. 
b. Control of covariation; we expect this to be very complex, probably involving more than 
either one of the classical mechanisms (common promoters, co-localization on chromosomes, 
common miRNAs, epigenetic modifications etc.); c. Functional meaning of the membership: 
given that except OLR1 itself few other members are involved in lipid metabolism, we assume 
that in fact other function(s) of LOX-1 will eventually explain this gene cluster. 
 
 
 
 
 
Diagram 3. Cardiovascular roles of OLRM members. 
The functions of these genes are given in Table 1. 
Projection of their functions over the vascular wall 
structure, as seen interacting with a generic 
mononuclear progenitor, suggests their common 
involvement in vascular protection and/or 
atherosclerotic plaque formation. Arrows indicate 
secreted proteins; dashed arrows indicate direct 
influences; in parenthesis are highlighted indirect 
relationships. EC = endothelial cells; SMC = smooth 
muscle cells; FB = fibroblasts; Mph = macrophages. 
(The hyperlink indicates the source of background 
drawing only). 
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